title: Preemptive transplantation--an analysis of benefits and hazards in 85 cases.
abstract: The benefit of transplantation without prior dialysis might be contravened by the failure to develop possible immunologic disabilities associated with chronic uremia and dialysis. This study compares graft and patient outcome, cyclosporine toxicity, pharmacokinetics, rejection episodes, nutritional status, and social and vocational rehabilitation between a preemptive group of 85 patients transplanted without prior dialysis and a cohort of 84 demographically, temporally, and disease-matched recipients of renal transplants after a minimum of 6 months' chronic dialysis therapy. The groups were matched for donor type, gender, and age, as well as immunologic risk factors of HLA-mismatch and percent panel-reactive antibody. All patients received CsA and prednisone immunosuppression. There were only two differences between the cohorts. The preemptive group included more diabetic patients: 32 versus 15 (P less than 0.01). The control cohort included more recipients who had received any pretransplant transfusion: 55 versus 28 (P less than 0.001). Both of these factors (if having any impact) would be expected to reduce graft survival in the preemptive group. All patients in the study had a minimum follow-up of 1 year and over half of the recipients are beyond 40 months. The preemptive patients showed survival rates of 94, 93, and 91 percent at 1, 2, and 5 years. These rates were not significantly different from those of the control group, namely 96, 96, and 93 percent, respectively. The actuarial graft survival rates in the preemptive group of 83, 81, 76, 73, and 73 percent at 1, 2, 3, 4, and 5 years were not statistically different from the control group rates, namely 90, 81, 80, 77, and 76 percent. Preoperative blood transfusion or percent positive panel-reactive antibodies had no effect on postoperative outcome in either group. The incidence of CsA nephrotoxicity was 9.4 percent in the preemptive group, which was not statistically different from the 17.9 percent in the control group. The incidence of rejection episodes in the absence of patient noncompliance was comparable between the groups. Seven of the irreversible rejection episodes in the preemptive group were due to noncompliance, compared with none in the control group (P less than 0.001). Preemptive recipients were also more likely than control group patients to be employed fulltime both before transplantation (36 vs. 22, P less than 0.05) as well as after transplantation (38 vs. 20, P less than 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)
authors.affiliation: Department of Surgery, University of Texas Medical School, Houston 77030.
authors.forename: S M
authors.initials: SM
authors.lastname: Katz
authors.forename: R H
authors.initials: RH
authors.lastname: Kerman
authors.forename: D
authors.initials: D
authors.lastname: Golden
authors.forename: J
authors.initials: J
authors.lastname: Grevel
authors.forename: S
authors.initials: S
authors.lastname: Camel
authors.forename: R M
authors.initials: RM
authors.lastname: Lewis
authors.forename: C T
authors.initials: CT
authors.lastname: Van Buren
authors.forename: B D
authors.initials: BD
authors.lastname: Kahan
mesh_terms: D001682:Biological Availability; D003524:Cyclosporins / Q000009:adverse effects / Q000378:metabolism; D006233:Persons with Disabilities; D004651:Employment; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000601:surgery* / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods*; D006435:Renal Dialysis; D012709:Serum Albumin / Q000378:metabolism; D016019:Survival Analysis; D014168:Transferrin / Q000378:metabolism
chemical_list: D003524:Cyclosporins; D012709:Serum Albumin; D014168:Transferrin